Epica International Secures $18M to Boost Medical Imaging and Robotics

Epica International, a Landrum, SC-based leader in advanced medical imaging and precision robotics, has successfully secured an $18 million growth capital loan. This new funding will help the company expand its business and develop new technologies for healthcare and manufacturing.

Key Details of the Funding

The loan was provided by Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P., both of which are part of the Avenue Capital Group. The initial $13.5 million of the loan will be used to refinance Epica’s existing debt and support the company’s growth. This includes expanding its operations and accelerating research and development. An additional $4.5 million is available, depending on the achievement of specific performance milestones.

The loan agreement spans four years and also includes a provision for Avenue Capital to receive a 0.5% equity stake in Epica International. Avenue Capital also has the option to invest an additional $2 million in equity over the next two years. Additionally, Avenue can convert up to $3.5 million of their loan into common stock at a price of $8.50 per share.

Epica’s Role in Healthcare and Robotics

Epica International, led by CEO Joe Soto, is known for its advanced medical imaging and precision robotics technologies. These technologies are widely used in both human and animal healthcare, as well as in scientific research. Epica’s patented medical imaging tools enable clinicians to achieve higher accuracy, leading to better outcomes for patients. These tools are also helpful in research, allowing scientists to work with more precise data.

Epica’s robotics division focuses on creating robotic solutions that help streamline manufacturing processes. These robots enhance production quality by combining precision engineering with advanced automation, which leads to higher efficiency and accuracy in manufacturing. This technology is used across a range of industries, helping businesses improve their production lines.

Patents and Innovations

Epica International currently holds 75 patents, with more pending, for its innovative medical imaging and robotics platforms. These patents are recognized not only in the U.S. but also in the European Union and other countries. This intellectual property highlights the company’s commitment to leading in both the healthcare and robotics fields.

Future Plans

With this new funding, Epica is set to grow its impact in the medical imaging and robotics industries. The growth capital will enable the company to continue developing its cutting-edge technology and expand into new markets. The additional capital available through the loan will be used for further advancements as the company hits key milestones.

Epica’s innovations in both healthcare and industrial robotics are expected to revolutionize these sectors. By continuing to develop technologies that enhance accuracy and efficiency, the company is well-positioned to drive positive change in both human and animal healthcare, as well as in manufacturing processes.

For more information about Epica International’s groundbreaking technologies and future developments, visit their website.

Battolyser Systems Secures €30M in Series A Funding to Advance Green Hydrogen Technology

Rotterdam-based Battolyser Systems has raised €30 million in Series A funding to scale its operations and bring its next-generation electrolyser to market by 2025. The funding round was backed by Global Cleantech Capital, Innovation Industries, and Invest-NL. This investment will help the company expand and further develop its innovative technology, which aims to revolutionize the production of green hydrogen.

A New Solution for Green Hydrogen Production

Battolyser Systems, led by CEO Mattijs Slee, has developed a groundbreaking device known as the “Battolyser.” This integrated battery and electrolyser can store electricity and produce hydrogen from renewable power sources. The ability to switch on and off quickly allows the Battolyser to balance energy supply and demand, making it highly efficient in supporting renewable energy grids. This flexibility helps reduce the cost of green hydrogen and eases grid congestion.

The Battolyser is available in a 2.5 MW plug-and-play format, as well as 5 MW modules, which can be installed with additional components on-site. This versatility makes it suitable for a wide range of applications, helping industries and communities transition to cleaner energy.

Scaling Up for 2025 Launch

The new funding will enable Battolyser Systems to scale up its production and prepare for the launch of its next-generation electrolyser in 2025. This will play a crucial role in making green hydrogen more accessible and affordable. The company is focused on leveraging renewable energy to produce hydrogen, which is expected to be a key component in reducing carbon emissions and meeting global climate goals.

Additional Support from the European Investment Bank

In addition to the €30 million raised in Series A funding, Battolyser Systems previously secured €40 million in financing from the European Investment Bank (EIB) in October 2023. This combined support will allow the company to accelerate its growth and bring its innovative technology to the market more quickly.

The EIB’s involvement underscores the importance of green hydrogen in Europe’s transition to a low-carbon future. With this significant financial backing, Battolyser Systems is well-positioned to lead the way in hydrogen production and renewable energy storage .

The Importance of Green Hydrogen

Green hydrogen, produced from renewable energy sources like wind and solar, is a critical solution for reducing carbon emissions in sectors that are difficult to decarbonize, such as heavy industry and transportation. By producing hydrogen using renewable energy, Battolyser Systems is helping to create a more sustainable energy future.

With the flexibility and efficiency of its Battolyser technology, the company is poised to make a significant impact on the green hydrogen market. The ability to store and produce hydrogen on demand makes it an ideal solution for addressing the challenges of intermittent renewable energy sources.

Looking Ahead

Battolyser Systems’ next-generation electrolyser is set to hit the market in 2025, and the company is already making strides toward scaling up its operations. With the support of its investors and the European Investment Bank, the company is on track to make green hydrogen a more viable and cost-effective energy solution for industries worldwide .

AltiusHub Secures $2.25M Seed Funding to Enhance Supply Chain Visibility

Manufacturing supply chain visibility software AltiusHub has raised $2.25 million in seed funding, led by Endiya Partners with participation from other investors. The funds will be used to strengthen its engineering team and hire industry-specific senior talent.

Founded in 2023 by Siddharth Reddy and Abiram Vijaykumar, AltiusHub aims to help manufacturing companies, particularly in the pharmaceutical sector, secure their supply chains. The company’s SaaS platform enables pharmaceutical firms to track and trace products throughout the production process, ensuring compliance with global regulatory standards such as US DSCSA, EU FMD, UAE Tatmeen, and India’s iVeda.

AltiusHub’s software focuses on preventing counterfeit medicines from entering the supply chain by providing real-time visibility into the movement of products. It detects patterns and anomalies that may indicate counterfeit activities, and alerts users immediately of any irregularities or deviations, allowing for quick intervention.

The startup’s focus on the pharmaceutical industry comes at a crucial time, as counterfeiting remains a significant issue worldwide. The platform’s advanced tracking and tracing capabilities are expected to enhance product integrity and safety across the supply chain.

With the global track and trace market projected to reach $7.3 billion by 2026, AltiusHub is well-positioned to capitalize on the growing demand for secure and transparent supply chains. The new funding will further support its mission to help manufacturers safeguard their supply chains and meet regulatory compliance.